Quintiles IMS Holdings, Inc. Get used to it. The world’s largest CRO and one of the leading global information and technology companies are now one. As their joint press release mentions, the rationale behind this merger is to improve this, create that, accelerate those, but what it comes down to is saving and making a lot of money. By “saving”, we mean an estimated $100M by the end of year three. Making money is not a new thing to either of these companies, but by combining their capabilities they aim to get a much larger chunk of the potential $230B market that is annually spent on drug development, Real-World Evidence services and commercial operations. With that kind of addressable market, the honeymoon phase for these two may never end.